Epha3 acts as proangiogenic factor in multiple myeloma.

Oncotarget (2017-04-19)
Antonella Caivano, Francesco La Rocca, Ilaria Laurenzana, Tiziana Annese, Roberto Tamma, Ubaldo Famigliari, Vittorio Simeon, Stefania Trino, Luciana De Luca, Oreste Villani, Simona Berardi, Antonio Basile, Angelo Vacca, Giuseppe Saglio, Luigi Del Vecchio, Pellegrino Musto, Daniela Cilloni
ABSTRAKT

This study investigates the role of ephrin receptor A3 (EphA3) in the angiogenesis of Multiple Myeloma (MM) and the effects of a selective target of EphA3 by a specific monoclonal antibody on primary bone marrow endothelial cells (ECs) of MM patients.EphA3 mRNA and protein were evaluated in ECs of MM patients (MMECs), in ECs of patients with monoclonal gammopathies of undetermined significance (MGECs) and in ECs of healthy subjects (control ECs). The effects of EphA3 targeting by mRNA silencing (siRNA) or by the anti EphA3 antibody on the angiogenesis were evaluated. We found that EphA3 is highly expressed in MMECs compared to the other EC types. Loss of function of EphA3 by siRNA significantly inhibited the ability of MMECs to adhere to fibronectin, to migrate and to form tube like structures in vitro, without affecting cell proliferation or viability. In addition, gene expression profiling showed that knockdown of EphA3 down modulated some molecules that regulate adhesion, migration and invasion processes. Interestingly, EphA3 targeting by an anti EphA3 antibody reduced all the MMEC angiogenesis-related functions in vitro. In conclusion, our findings suggest that EphA3 plays an important role in MM angiogenesis.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
MISSION® esiRNA, targeting human EPHA3
Sigma-Aldrich
MISSION® esiRNA, targeting human MAX

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.